Couldn't disagree with you more.
You're taking a broad brush and saying HCQ is bad period. The Lancet study shows that as it has been used in the past can produce net negative outcomes, but that doesn't mean that used properly with the right patients it cannot be a very positive treatment. Include zinc with the HCQ and only give to patients early enough in the disease progression for there to be time to knock down the viral counts and prevent the massive battle in the lungs. The NYU study shows enormous benefit of including zinc and also shows that for good results the treatment needs to begin before the patient is transferred to ICU.
View attachment 544225
Let's talk about this excerpt from Chart 4 of the NYU study. When HCQ+azithromycin+zinc was given to patients before ICU admission, 6.9% of patients either died or were moved to hospice. In contrast when zinc was excluded in that same scenario 13.2% of patients died or were moved to hospice. The .449 number gives the gains in preventing death that came from adding zinc when given before the patient reached the ICU.
Regarding the possible heart issues from HCQ, it really comes down to administering the treatment in a fashion that minimizes the risks and maximizes the benefits in order for the improved outcomes to significantly outweigh the risks of the treatment. As a patient becomes more severe with COVID19, the heart issues can become more apparent, both because of the patient's condition and other medications given that promote heart arrhythmia. This is a big part of the reason why the Lancet article showed negative results from HCQ. Given too late in the progression, the risks of the treatment clearly outweigh the benefits.
Why then give HCQ at all and take a risk? It's because for certain groups of at-risk patients, COVID19 can be a very deadly disease. You don't want to give the HCQ and zinc treatment to a young person who is not in an at risk group, but you may well be saving the patient's life by giving the treatment upon first indication of the disease when the patient is in an at risk group..
You say that you proved that the 44% improvement in fewer deaths is something you've already shown. I watched closely, and all you said was you have to use the study instead of the article. So, I read the NYU study and the chart 4 comes from that study. It backs up what the article says.
I ask you to show with data why this significant improvement really isn't an improvement. Don't descend to belittling the person with an opposing view. Keep this discussion professional. Thank you.